semaglutide and cushing's GLP-1 diabetes weight-loss drug side effects: "Ozempic face" and more Anti-obesity Medications and Muscle Loss

The body begins transitioning to fat oxidation as the primary fuel source

Seventh, we were not able to examine the importance of duration of exposure in the analyses, as the relative rarity of NAION would decrease the statistical power of the study considerably and also violate the General Data Protection Regulations that individualized patients should not be identifiable in register-based studies

A., Mesawa, M., Rizk, H., & Iv, A

Lilly's 2025 data shows Zepbound maintains efficacy for two-plus years with continuous use

Eli Lilly has announced promising results from its first Phase 3 clinical trial for orforglipron , a once-daily oral GLP-1 receptor agonist